In this retrospective study, we evaluated the chimerism status and outcome in 58 patients (64 transplants) with non-malignant diseases. Reduced intensity conditioning (RIC) was given in half of the transplants. Mixed chimerism (MC) was defined as 41% recipient cells. Two consecutive samples showing 430% recipient cells were defined as high chimerism (high MC). Patients with high MC and the management of these patients were analyzed in greater detail. The overall survival rate was 87%. In total, 23 transplants were donor chimerism (DC) and 41 transplants showed some degree of MC. The incidence of MC was 78 and 50% after RIC and myeloablative conditioning, respectively (P ¼ 0.04). Acute GVHD of grades II-III was more common in patients with DC (39%) than in patients with MC (8%) (P ¼ 0.002). Owing to high MC, donor lymphocyte infusions were given in 17 cases. The level of MC was reduced in seven cases, unchanged in four cases, increased in one case and there was graft rejection in five cases. A second transplant was carried out in six cases with rejections, five are alive and in remission. We conclude that patients with non-malignant diseases, who develop MC after transplant have less acute GVHD. Despite the high incidence of MC, overall survival is promising.
Introduction
Allogeneic hematopoietic SCT (AHSCT) is an established optional therapy for several non-malignant diseases including hemoglobinopathies, severe immunodeficiencies and metabolic disorders. 1, 2 The aim of transplantation in these diseases is to achieve sustained engraftment to improve hematopoietic function, provide immune competence or increase or normalize enzyme deficiency. Chimerism is commonly used to monitor engraftment after AHSCT. Although used in patients with malignant hematological disorders, mainly to diagnose early relapse after AHSCT, it has been shown to be valuable in the detection of graft failure or rejection, and also to predict GVHD, two common causes of treatment failure in patients transplanted for non-malignant diseases. [3] [4] [5] Most of the non-malignant diseases have autosomal recessive inheritance and result from reduction or lack of function of enzymes. It has been debated whether replacing only a proportion of the diseased cells, that is, inducing mixed chimerism (MC), will abolish all signs of disease and, furthermore, whether a disease-carrying sibling donor would be superior to an unrelated, HLA-identical healthy donor. 2 Graft failure and graft rejection are known to be high in patients with non-malignant diseases. 6, 7 This may be because of the fact that there has been no earlier chemotherapy to the risk of immunization from repeated transfusions in hemoglobinopathies, and to the use of less myeloablative-conditioning regimens. In recent years, an increasing number of patients with non-malignant diseases have been treated with reduced intensity conditioning (RIC) to reduce acute toxicity and late side effects. 8 This may lead to more patients with MC.
In this retrospective study, we investigated the chimerism status after AHSCT in 58 patients with non-malignant diseases. We wanted to see how the clinical outcome was in correlation to the chimerism status and to what extent the patients responded to different immunomodulatory treatments.
Materials and methods

Patients
Between 1997 and 2007, we performed AHSCT in 60 patients with non-malignant diseases. One patient with SCID and one with Wiskott-Aldrich syndrome were excluded because of the lack of chimerism data. The 58 patients included in this study were 27 patients with severe hematological defects, 12 patients with histiocytic disorders, eight with immunodeficiencies, six with lysosomal disorders, three patients with leukodystrophies and two siblings with a glycoprotein disorders-aspartylglucosaminuria (AGU). Median age was 7 years (range 0-64). Characteristics of the 58 patients and their donors are given in Table 1 .
Outcome definitions
In patients with non-malignant diseases, there is no clear consensus about the definition of clinical remission. In this study, a patient was defined as being in remission if the disease did not progress after transplant. For example, a patient with Hurlers syndrome, with normal neurological development and disease markers, but hearing impairment, dysostosis multiplex and in need of correctional orthopedic surgery would be defined as being in remission. 9, 10 Patients were defined as being in PR if some positive effects of AHSCT was seen-for example, a patient with Thalassemia major with some improvements, but still transfusion dependant-or as having disease progression in which no positive effect of AHSCT has been noted.
Donors
HLA-A, -B, -DRB1 identically matched unrelated donors (MUD) and HLA-identical sibling donors were used in 35 and 19 of the patients, respectively. Of the nine HLAmismatched unrelated transplants, five received cord-blood units. HLA class I and class II typing was carried out by PCR using sequence-specific primer pairs.
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Conditioning
Most of the 27 patients with severe hematological defects were given BU at a dose of 80 mg/m 2 (4-5) mg/kg for 4 consecutive days (day-9 onto day-6), followed by CY at 2 g/m 2 (50-70 mg/kg) for 4 days (day -5 to day -2). 12 Patients with Fanconi anemia were conditioned with fludarabine at 30 mg/m 2 per day for 5 days, followed by CY at 60 mg/kg per day for 2 days. 13 The nine patients with immunodeficiencies were mainly given BU and CY. All of the patients with lysosomal disorders were given BU followed by CY, except for one, who received fludarabine followed by Treo. Three patients with leukodystrophies received either BU and CY (two cases) or CY followed by fractionated TBI (one case), as did the two patients with AGU. In total, RIC was carried out in 32 of 64 transplants. All patients except three received either rabbit antithymocyte globulin (Thymoglobulin; IMTIX, Sangstat-Lyon, France) at 2 mg/kg per day for 3-4 days or OKT-3 (Janssen-Cilag, Zug, Switzerland) at 5 mg/day for 5 days.
GVHD prophylaxis and treatment GVHD prophylaxis mainly consisted of CsA combined with MTX (32 cases). In 13 patients, MTX was replaced either with mycophenolate mofetil (eight cases) or prednisolone (five cases). Seventeen patients received tacrolimus (FK, Astellas Ireland, Killorglin, Ireland) together with Rapamycin (Sirolimus, Wyeth Medical Ireland, Newbridge, Ireland) and one in combination with MTX. Two patients received T-cell depleted grafts. Trough levels of CsA and FK in whole blood during the first 3 months after transplant were 200-300 and 5-15 ng/ml, respectively. The dose was tapered after 12-18 months and discontinued after 1.5-2 years in the absence of acute or chronic GVHD. Mycophenolate mofetil and Rapamycin were tapered after 3 months in patients without GVHD. Trough levels of Rapamycin in the first 3 months were 3-12 ng/ml. Grade-1 acute GVHD was treated with prednisolone at 2 mg/kg per day for a week or more, and tapered depending on the response.
Specimens and chimerism analysis
Peripheral blood samples were collected from the donor and recipient before transplantation and from the recipient on a monthly basis after AHSCT. DNA from donor and recipient pre-transplantation samples was extracted using standard protocols (Qiagen, Hilden, Germany). To evaluate lineage-specific chimerism, selection of T cells (CD3 þ ), B cells (CD19) and myeloid cells (CD13 þ , CD33 þ or CD45 þ cells) from peripheral blood was done using immunomagnetic beads (Dynal, Oslo, Norway).
14 Chimerism data were collected 1, 3, 6 and 12 months after AHSCT and at the last follow-up. In patients with high MC, all available data were collected.
Techniques for detection of recipient cells in a donor environment have varied over the years. Between 1997 and 2001, as we earlier described, chimerism analysis was on the basis of the use of variable numbers of tandem repeats, minisatellites, as a separation marker. 14 
Chimerism definition
For chimerism results, we used the same definitions as used by others. 17 Patients whose samples showed no autologous cells or o1% at any time after transplant were considered to have complete donor chimerism (DC). The level of 1% was chosen, as the microsatellites and variable numbers of tandem repeat methods have a sensitivity limit of 1-5%, whereas the real-time PCR method has a sensitivity of 0.01%. 15 MC was defined as having a recipient fraction of between 1 and 99%. Patients with MC were also divided into three subgroups: (1) those with high MC, defined as having 430% recipient DNA in two consecutive samples, (2) those with stable MC, with consistent recipient levels of o30% and (3) those with decreasing MC, when an initial stable MC turned into DC.
Chimerism results in different cell lineages were not presented separately because of the fact that they were mostly coherent after AHSCT. In a minority of cases, in which lineage chimerism values were different, the T-cell or myeloid lineage with the highest recipient levels defined the chimerism status.
Statistics
Survival and incidence curves were generated using the Kaplan-Meier method. For univariate and multivariate analysis, the Cox proportional hazards regression model was used. Mann-Whitney U-test and Fisher's exact tests were used to evaluate differences between groups. Analyses were carried out using Statistica software (StatSoft, Tulsa, OK, USA).
Results
Survival
The overall survival was 87% (Figure 1 ). Follow-up time for patients who were still alive was a median of 4.3 years (range 0.4-10.6). Six patients died. Two patients died within 3 months of AHSCT because of infections, one patient with FA because of secondary malignancy and one patient with hemophagocytic lymphohistiocytosis because of post-transplant lymphoproliferative disease. One patient with ALD, who had disease progression, died because of hemorrhage caused by lack of factor VIII and one patient with Kostmann syndrome, who was undergoing treatment with donor lymphocyte infusions (DLI) because of high MC, died 10 month after AHSCT mors subita at home because of an unknown cause.
Chimerism
Mixed chimerism was detected in 41/ 64 (64%) transplants. Out of these 41 transplants, 26 were high MC, whereas the rest showed either decreasing or stable MC (Table 2) .
Although chimerism results usually were coherent in different cell lineages, some patients had distinctive chimerism patterns. In eight out of nine patients with Fanconi anemia, recipient cell levels were higher in the Tcell fraction as compared with the B-cell and myeloid-cell fractions. The difference was usually 420%. In one patient with SCID, high recipient levels (460%) were detected in the B-cell and myeloid-cell fractions, whereas T cells were completely of donor origin. A similar pattern was also detected in the only patient with Wiskott-Aldrich syndrome. transplants (74%) with HLA-identical sibling donors (P ¼ 0.15). A total of 9 out of 10 HLA-mismatched grafts developed MC, which was significantly more than matched unrelated donor transplants, P ¼ 0.03. Eight patients with graft rejection had matched unrelated donors, one of which was a HLA-matched cord-blood transplant.
Donor type and chimerism
Graft type and chimerism
There was no significant difference in MC development between patients receiving BM (27/42) and PBSCs (6/14). However, all eight transplants (seven patients) with cord blood showed MC: three stable MC and five high MC. One patient had rejection of the first cord-blood transplant, was transplanted again with a double cord blood, and subsequently rejected this. The six other patients with cord-blood transplants are in remission.
Conditioning regimen and chimerism
The incidence of MC was 50% (16/32) after myeloablative conditioning, as compared with 78% (25/32) after RIC (P ¼ 0.036). The incidence of high MC in the two groups was 38% (12/32) and 44% (14/32), respectively (not significant).
GVHD
None of the patients developed acute GVHD grade IV.
Patients with DC after AHSCT had a higher incidence of acute GVHD grades I-III (Po0.0001) and grades II-III (P ¼ 0.002), as compared with patients with MC ( Figure 2 ). Conditioning regimen also had an influence on acute GVHD; 61% of patients with myeloablative conditioning were diagnosed with GVHD grades I-III as compared with 30% in patients treated with RIC (P ¼ 0.007) (Figure 3) . In multivariate analysis for acute GVHD grades II-III including factors such as age, donor type, cell dose, chimerism, conditioning, HLA matching and stem cell source, DC was the only significant risk factor for the development of acute GVHD of grades II-III (OR 6.1, 95% CI 1.7-22.6, P ¼ 0.007).
Chronic GVHD did not significantly differ between transplants with MC (18%) and those with DC (22%).
Chimerism and outcome
The relationship between chimerism status and clinical outcome is shown in Table 2 . Of 23 patients with DC, 21 are presently in remission, one is in PR (a patient with metachromatic leucodystrophia, with mild neurological deterioration) and one patient, with ALD, transplanted with advanced neurological symptoms, had disease progression and subsequently died 3.5 years after AHSCT. All 15 patients with either decreasing or stable MC are doing well and in remission, except a young girl with thalassemia major, who is still transfusion-dependant and thus in PR. All of the transplant rejections (n ¼ 9) and five out of six deaths were found in the group of patients with high MC.
Management of patients with high MC
There is no established therapy for MC or high MC in patients with non-malignant diseases after AHSCT. Thus, different modalities were attempted (Table 3) . Of 24 patients, who were defined as having high MC, two Chimerism analysis in patients with non-malignant diseases P Svenberg et al patients had no active treatment, one patient died with rejection and in one patient with AGU, immunosuppression was tapered 3 years after AHSCT. In the AGU patient, there was a slowly increasing MC (60-80% in the T-and myeloid linages 9 years after AHSCT), but the disease was in remission; that is, there was improved neurological development compared with untreated patients. It is interesting that his female sibling with AGU and 10 years after AHSCT has similar clinical outcome, but is a full donor in all cell lineages. 18 In three patients in whom immunosuppression was reduced, two had decreasing MC and one had no change in MC. All the three are currently in remission. In two patients, immunosuppression was increased and both developed DC, and are in remission. Out of them, a girl with thalassemia major was given prednisolone because of hemolytic anemia and thereafter developed DC.
Donor lymphocyte infusion was administered to 15 patients because of high MC (corresponding to 17 transplants, as two received DLI also after the second AHSCT). Seven transplants subsequently developed decreasing or stable MC, but in 10 cases no change or increased MC was seen. Five of these patients had graft rejection (Table 3) . DLI was administered at a median time of 3 months (range [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] , and the median number of infusions was one (range 1-5). Median cell dose was 1 Â 10 6 (range 1 Â 10 5 -1 Â 10 8 ) T cells/kg recipient. A total of 2/15 (13%) developed mild acute GVHD and all patients, but one, underwent DLI during ongoing immunosuppression. Median MC was 65% (range 40-100%) before DLI, and in the cases in which DLI seemed to have an effect, that is, decrease in recipient cell levels, median MC was 50% (range 40-85%), whereas in the cases in which DLI apparently was ineffective the median MC was 70% (range: 40-100%). It is interesting that none of the patients with 450% recipient cells in both T-cell and myeloid-cell fractions responded to DLI. Anti-T cell antibody (OKT-3) was given on five occasions before DLI. No pancytopenia was observed after DLI.
In three of the patients, we found exceptional high MC (480% recipient cells), but the patients were still in remission. A boy with hemophagocytic lymphohistiocytosis, with normal disease markers and normal neurological development, underwent AHSCT 5 years ago and has been without immunosuppression for 2 years. A girl with Hurlers syndrome, whose first graft was rejected after 2 months, also received DLI after the second AHSCT. At 3 years after retransplantation, there has been normal CNS development and slightly elevated u-glucosamino-glykans 22 g/mol creatinine. 
Retransplantation
Eight patients rejected their grafts, all of whom were in the high MC group. The stem cell source was BM in seven cases and cord blood in one case. Six patients were retransplanted, and all received fludarabine-based RIC regimens. Median time to retransplantation was 5 months (range 1.2-16) after the first AHSCT. Retransplantation was carried out using the original donor in three of the six cases. Five of these six patients are still alive, four are in remission with DC and one is in remission with high MC. A boy with Fanconi anemia, who was heavily transfused before AHSCT and who had multiple anti-HLA antibodies rejected two consecutive cord blood transplants and died one month after the second transplantation.
Discussion
Allogeneic hematopoietic SCT for patients with many non-malignant diseases is a curable therapy. Although the population is heterogeneic, we wanted to evaluate the chimerism and clinical outcome in our most recently transplanted patients.
The 58 patients eligible for evaluation had an encouraging overall survival rate of 87%, which agrees well with other studies involving patients with non-malignant diseases and severe hematological disorders. The overall incidence of acute GVHD was relatively low in this study, and no patient died of acute GVHD. Patients with DC had a higher risk of acute GVHD compared with MC patients. In an earlier study, including mainly patients with hematological malignancies, we also showed that T-cell DC is associated with a higher risk of developing severe acute GVHD. 4 Not surprisingly, we experienced more patients with MC after conditioning with RIC than with myeloablative conditioning, which has been described by others. [21] [22] [23] More importantly, however, high MC was no different using RIC than with myeloablative conditioning. High MC was correlated with graft failure and it is therefore undesirable. Low levels of recipient cells may be welcome in these patients, as it reflects a decreased allo-response. GVHD is a major complication, and it is associated with increased infections and mortality after AHSCT. Patients with non-malignant diseases do not benefit from a graftversus-tumour effect, and therefore GVHD should be avoided in these patients. In this study, acute GVHD was more common in myeloablative patients, which coincide with the fact that these patients have more DC.
It is known from other investigations that high MC correlates with an increased risk of rejection. 24 All patients in this study, who experienced graft rejection were in the high MC group. Although most of the grafts in the patients with high MC (14/26) had a favorable outcome, all deaths, but one, occurred in the high MC group. Different kinds of management of patients with high MC included increasing or decreasing of immunosuppression and administration of DLI, and two patients received no treatment at all.
Immunosuppression was either increased or decreased in few patients (three and two patients, respectively) with high MC, which is why clearly no conclusions can be made. Of the 10 cases, which did not respond to DLI, MC was probably too high and the recipients' immune system was too strong. Furthermore, as the majority of patients were still on immunosuppression, the effect of new lymphocytes may have been limited. The reason for continued immunosuppression during DLI treatment was to avoid GVHD in these patients. However, discontinuation of immunosuppression is probably necessary before DLI, especially in patients with high MC. From a number of studies on patients with malignant diseases and some studies on metabolic disorders, we have learned that in cases of increasing recipient chimerism, immunosuppression should be discontinued before DLI for optimal effect. 3, 17, 25 From a historical perspective, retransplantation has been associated with increased morbidity and mortality, 7, 26 although younger patients have superior outcome. 27 Our experience on the basis of this restricted material shows that patients with non-malignant diseases do well after retransplantation.
In this retrospective study, patients with non-malignant diseases after AHSCT had an overall survival rate of 87%. We conclude from this work that patients with MC have less risk of developing GVHD and that patients with high MC have a greater risk of rejection, although patients who needed a second transplantation did surprisingly well. 
